Company intelligence / Profile preview

Sernova Biotherapeutics

London, Ontario, Canadasernova.com ↗

Ownership: Private
Employees: ~17
Development stage: Other

Overview

Sernova’s lead program is a Phase 1/2 trial of its Cell Pouch with human donor islets in patients with type 1 diabetes. Early results show the device can support engraftment and function of transplanted islet cells, aiming to restore endogenous insulin production. The company also has preclinical programs targeting hypothyroidism using the same platform.

Therapeutic areas: Endocrinology
Modalities: Cell therapyDevice (bio-hybrid organ implant)Induced pluripotent stem cell derived therapy
Industry: Biotech

Drug pipeline

5 assets

SR59230A

Preclinical

4 more assets in the full pipeline.

Request access →

Partnerships

Evotec AG — strategic partnership to develop iPSC-based islet-like clusters for T1D treatment using the Cell Pouch platform.

Beyond the preview

Go deeper on Sernova Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sernova Biotherapeutics.

Explore the full profile